Wize Pharma Inc. announced that Bonus BioGroup has initiated a preclinical study of its drug product candidate MesenCure, specifically developed to potentially treat acute and life-threatening respiratory distress and pneumonia whether as a result of infection with coronavirus (COVID-19), or any other type of virus, bacterial infection, or exposure to other contaminants. Bonus BioGroup has reported that preliminary efficacy data from the MesenCure study are expected in May 2020, with study completion anticipated in the third quarter of 2020.